NADMED Launches 2026 Award to Accelerate Redox Metabolomics Discoveries
Finnish biotechnology company NADMED has announced the launch of the NADMED Award 2026, positioning it as a catalyst for fresh discoveries in metabolomics.
The initiative is designed to empower scientists and clinicians to investigate key cellular processes linked to metabolism, ageing and disease – areas where subtle molecular shifts can carry outsized implications for health.
At the heart of the programme is access: by opening up its advanced metabolomics platform to applicants, NADMED says it wants to encourage discovery, collaboration and innovation across the biomedical sector, particularly in domains where specialist tools and high costs can slow progress.
“Lowering the barriers” to redox metabolism research
A central ambition of the NADMED Award, according to the company’s chief marketing officer, is to reduce the friction that often prevents teams from exploring what has historically been difficult to measure: the dynamics of redox metabolism.
By making NADMED’s tools available to the wider research community, the company believes it can help accelerate discoveries that could reshape how researchers understand cellular function and disease mechanisms.
That framing speaks to a broader reality in modern bioscience: it’s not just which molecules are present, but how they change over time – and how cellular systems respond under stress – that can unlock new hypotheses and, ultimately, new diagnostics and interventions.
Three categories designed to match the development journey
Rather than a one-size-fits-all grant model, the NADMED Award 2026 is comprised of three categories, intended to support different stages of progress.
These are Innovative Ideas, Advanced Research, and Clinical Data Research – a structure that signals an interest in helping early concepts get off the ground while also supporting more mature scientific work and clinically oriented investigations.
The award is open to applications from academic institutions, clinical laboratories, pharmaceutical companies, and biotechnology innovators, with submissions set to be judged by a panel of global experts.
What winners receive – and why it matters
Winning projects will receive CE-marked metabolomics kits, expert consultation, and in-house measurement services valued at up to $30,000.
For research teams, that combination can be particularly meaningful: it offers not only tools, but also specialist support and measurement capacity that can be hard to access without significant internal infrastructure.
Crucially, the prize is framed as a practical accelerator – reducing set-up barriers and enabling researchers to move from question to dataset more efficiently, especially in areas where measurement quality and consistency are essential.
A platform with roots in Helsinki – and a diagnostic horizon
Founded in 2022 as a spin-out from the University of Helsinki, NADMED has built technology capable of quantifying all four forms of nicotinamide adenine dinucleotide as well as both reduced and oxidised glutathione directly from biological samples.
The company says this capability has the potential to uncover valuable diagnostic insights across both research and clinical settings – particularly where redox balance and metabolic dynamics are thought to be playing a pivotal role.
Expert backing and a fixed date for the verdict
A member of the NADMED Award jury described the initiative as a powerful way to stimulate discovery across multiple fields of biology and medicine – an endorsement that reflects the award’s cross-disciplinary intent.
NADMED has confirmed that the results of the NADMED Award 2026 will be announced on 28 February 2026, giving applicants and observers a clear milestone for when winning projects – and their research direction – will be revealed.
Conclusion
With the launch of the NADMED Award 2026, NADMED is placing a firm bet on the idea that enabling access to high-end metabolomics can unlock meaningful advances in how science understands metabolism, ageing and disease.
By offering three development-aligned categories, opening applications to academia and industry, and providing up to $30,000 in CE-marked kits, expert guidance and measurement services, the Finnish biotech is aiming to lower barriers to redox metabolism research and spark collaboration across the biomedical landscape -setting the stage for new insights when results are announced on 28 February 2026.
News Credits: NADMED launches $30,000 metabolomics research award
Things you might also like:
- Richmond Doubles Down on Meat-Free with ‘Veggie Tasty’ Sausages Range
- Sobi Moves to Bolster Its Gout Pipeline With Arthrosi Deal
- Lindus Health and Quotient Sciences Partner